107 completed, 35 terminated, 10 recruiting, 6 withdrawn. 117 Phase 2, 70 Phase 1, 11 Phase 3, 2 Not applicable.
Follow Clofarabine: new trials by email Literature Review of Clofarabine trials Research Report on Clofarabine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cord Blood Transplantation in Children and Young Adults With Blood Cancer Cord Blood Units, Total Body Irradiation, Cyclophosphamide - Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 71 | 2026-04-28 | 2026-05-14 |
| Phase 1b/2a Trial of Allogeneic HSCT From an HLA-partially Matched Related or Unrelated Donor After TCRab+ T-cell/CD19+ B-cell Depletion for Patients With Monogenic and/or Early-onset Medically Refractory Crohn Disease CliniMACS® TCR α/β Reagent Kit and CliniMACS® CD19 System, Prednisone/Methylprenisolone, Palifermin - Crohn Disease | Phase 1 / Phase 2 | Not yet recruiting | Stanford University | 14 | 2025-07-01 | 2025-05-23 |
| Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocytosis in Children Dabrafenib or Trametinib and Clofarabine - Langerhans Cell Histiocytosis (LCH) | Phase 2 | Recruiting | West China Second University Hospital | 20 | 2025-06-01 | 2025-06-15 |
| Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation Methotrexate, Post-Transplant Cyclophosphamide, Fludarabine - Graft Versus Host Disease, Hematologic Malignancy | Phase 2 | Recruiting | Nantes University Hospital | 82 | 2024-07-18 | 2026-01-26 |
| Clofarabine Therapy in Locally Advanced or Metastatic Urothelial Carcinoma Clofarabine - Advanced Urothelial Carcinoma, Metastatic Urothelial Cancer | Phase 1 / Phase 2 | Recruiting | Ekaterina Laukhtina | 50 | 2023-10-24 | 2025-06-26 |
| Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT Fludarabine, Busulfan, ATG - Acute Myeloid Leukemia in Remission | Phase 2 | Recruiting | Nantes University Hospital | 302 | 2023-09-14 | 2026-01-30 |
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 23 | 2023-08-11 | 2026-08-06 |
| Uproleselan With Pre-Transplant Conditioning in Hematopoietic Stem Cell Transplantation for AML Uproleselan, Fludarabine, Clofarabine - Acute Myeloid Leukemia, Pediatric Cancer | Phase 1 | Terminated | Malika Kapadia | 1 | 2022-10-06 | 2024-08-19 |
| Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML busulfan, cyclophosphamide and melphalan, BuCyMel, clofarabine, fludarabine and busulfan, CloFluBu - Acute Myeloid Leukemia (AML) in Remission, Stem Cell Transplantation | Phase 3 | Recruiting | Vastra Gotaland Region | 170 | 2022-06-07 | 2024-12-19 |
| Vorinostat and Combination Chemotherapy Before Donor Stem Cell Transplantation for the Treatment of Relapsed Aggressive B-cell or T-cell Non-Hodgkin Lymphoma Allogeneic Hematopoietic Stem Cell Transplantation, Busulfan, Clofarabine - Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2021-10-29 | 2024-01-12 | |
| Bisantrene Combination for Resistant AML Bisantrene, Fludarabine, Clofarabine - Myelogenous Leukemia, Acute | Phase 2 | Unknown | Sheba Medical Center | 29 | 2021-08-02 | 2023-11-28 |
| Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders Clofarabine, Fludarabine, Busulfan - AML, ALL | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 31 | 2020-11-20 | 2026-03-13 |
| Vyxeos® With Clofarabine for Pediatric AML Vyxeos 44 MG / 100 MG Liposome Injection, Clofarabine - Relapsed Pediatric AML, Refractory Pediatric AML | Phase 1 | Recruiting | Princess Maxima Center for Pediatric Oncology | 25 | 2020-11-06 | 2025-09-05 |
| Clofarabine Pre-conditioning Followed by Stem Cell Transplant for Non-remission AML Clofarabine, Fludarabine, Busulfan - Acute Myeloid Leukemia | Phase 2 | Terminated | Milton S. Hershey Medical Center | 2 | 2020-06-03 | 2023-09-14 |
| Donor Stem Cell Transplantation Using α/β+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors Hyperfractionated total body irradiation, Thiotepa, Cyclophosphamide - Acute Lymphoid Leukemia (ALL), Acute Myeloid Leukemia (AML) | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 9 | 2018-07-25 | 2025-04-06 |
| TCR Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors Melphalan, Thiotepa, Clofarabine - Non-Malignant Hematologic Disorders | Phase 2 | Terminated | Memorial Sloan Kettering Cancer Center | 1 | 2018-07-23 | 2021-03-24 |
| Post Transplant Cyclophosphamide (PTCY) as Sole Graft Versus Host Disease (GVHD) Prophylaxis for Matched Allotransplant: CYRIC Fludarabine, Clofarabine, Full body irradiation - Graft Versus Host Disease | Phase 2 | Terminated | Nantes University Hospital | 47 | 2018-01-15 | 2022-07-15 |
| Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or Lymphoma Anti-Thymocyte Globulin, Busulfan, Clofarabine - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia | Phase 2 | Completed | M.D. Anderson Cancer Center | 6 | 2017-10-13 | 2023-10-11 |
| Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia Bortezomib, Clofarabine, Cyclophosphamide - Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 42 | 2017-08-09 | 2026-08-10 |
| Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma Prednisone, Vincristine, Daunorubicin - Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma | Phase 2 / Phase 3 | Active not recruiting | St. Jude Children's Research Hospital | 790 | 2017-03-29 | 2026-06-17 |
Showing 20 of 167. Sign in to see all of them.
Leukemia, Myeloid, Acute (84) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (58) · Leukemia (54) · Myelodysplastic Syndromes (49) · Lymphoma, Non-Hodgkin (19) · Congenital Abnormalities (15) · Hodgkin Disease (13) · Leukemia, Lymphocytic, Chronic, B-Cell (13) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (13) · Lymphoma (13) · Recurrence (13) · Leukemia, Myelomonocytic, Chronic (11) · Leukemia, Erythroblastic, Acute (10) · Leukemia, Megakaryoblastic, Acute (10) · Leukemia, Monocytic, Acute (10)
M.D. Anderson Cancer Center (31) · Genzyme, a Sanofi Company (15) · St. Jude Children's Research Hospital (12) · Memorial Sloan Kettering Cancer Center (8) · Masonic Cancer Center, University of Minnesota (5) · Nantes University Hospital (5) · Fred Hutchinson Cancer Center (3) · Massachusetts General Hospital (3) · Milton S. Hershey Medical Center (3) · National Cancer Institute (NCI) (3) · Therapeutic Advances in Childhood Leukemia Consortium (3) · University of Washington (3) · Washington University School of Medicine (3) · Baylor Research Institute (2) · City of Hope Medical Center (2)
United States (132) · France (10) · Italy (9) · Germany (7) · Canada (6) · Netherlands (4) · United Kingdom (4) · Austria (3) · Israel (3) · Spain (3) · Australia (2) · Belgium (2) · China (2) · Denmark (2) · Hong Kong (2)
Stefan Faderl, MD (5) · Sima Jeha, MD (4) · Elizabeth Shpall, MD (3) · Pamela Becker (3) · Anjali Advani, MD (2) · Bayard L. Powell, MD (2) · Edward Agura, MD (2) · Hagop Kantarjian, MD (2) · Hiroto Inaba, MD, PhD (2) · Maria Cancio, MD (2) · Paul Orchard, MD (2) · Ravi Vij, M.D. (2) · Seah Lim, MD (2) · Sherif Farag, MD, PhD (2)
PMID 29702001, PMID 39121442, PMID 10499616, PMID 11071652, PMID 11222401, PMID 12637486, PMID 12791647, PMID 1348362, PMID 14551141, PMID 15049016, PMID 15381930, PMID 15486072, PMID 16304375, PMID 16403905, PMID 16609072, PMID 16622268, PMID 1707752, PMID 17562873, PMID 17611569, PMID 18565853, PMID 18623218, PMID 19731321, PMID 20026805, PMID 20085940, PMID 20946966, PMID 21425150, PMID 21586746, PMID 21841163, PMID 21967976, PMID 22080968, PMID 22585697, PMID 22801963, PMID 23234514, PMID 23255383, PMID 23589673, PMID 24081577, PMID 24415560, PMID 24951467, PMID 24970932, PMID 25087182, PMID 25545153, PMID 25778529, PMID 26194764, PMID 26283567, PMID 26376115, PMID 27171984, PMID 27374466, PMID 27561720, PMID 28396162, PMID 29020310
2008 (3), 2009 (2), P01CA148600 (2), P30CA006973 (2), P30CA015704 (2), P30CA016672 (2), R01CA138744 (2), U10CA032102 (2), 2023 (1), F32CA141762 (1), P01CA078902 (1), P30CA008748 (1), P30CA016086 (1), P30CA033572 (1), P30CA036727 (1)